MENU

Company news

ImmuneOnco sets up wholly-owned subsidiary—ImmuneOnco BioPharm (Shanghai) Co., Ltd.

Date:2021-09-28 Views:271


    On September 28, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") wholly-owned subsidiary-ImmuneOnco BioPharm (Shanghai) Co., Ltd. was established in Zhangjiang Science City (hereinafter referred to as "ImmuneOnco BioPharm"). ImmuneOnco BioPharm is the pharmaceutical manufacturer for the company ImmunOnco. The establishment of the company marks the formal formation of ImmuneOnco’s strategic layout from the development and research of anti-tumor immunotherapy products to the integrated development and drug manufacture. It will provide powerful assistance for industrialization of newly developed products.



   

    Tian Wenzhi, the founder and chairman of ImmuneOnco, said: "The settlement of ImmuneOnco BioPharm marks the development of ImmuneOnco into a new stage, which fully explains ‘changing with each passing day’, the ImmuneOnco speed. ImmuneOnco BioPharm shoulders a major mission for 'Project of constructing Base of ImmuneOnco Headquarters and Biopharmaceutical Industrialization '. We expect to expand our developmental advantages of anti-tumor products of immunotherapy in the future and accelerate the advancement of clinical trial research as well as the pace of product industrialization, so as to benefit cancer patients as soon as possible."




About ImmuneOnco

    Founded in June 2015 at Zhangjiang Hi-Tech Park of China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bi-specific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy. Our compounds aim to activate patients’ own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can return gradually to being healthy. Currently, several new anti-tumor products are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winners of the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.